Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 4/20 | 0.37 |
| ▸ | CDK2 | P24941 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31633436 | 1.00 | CCNA2 (0.37) | CCNA2CDK2MAPTMEN1KMT2A | |
| SCHEMBL30211003 | 0.92 | MAPT (0.36) | CCNA2CDK2MAPTMEN1KMT2A | |
| SCHEMBL30437290 | 0.90 | MAPT (0.37) | CCNA2CDK2MAPTMEN1KMT2A | |
| SCHEMBL23930496 | 0.90 | MAPT (0.37) | CCNA2CDK2MAPTMEN1KMT2A | |
| SCHEMBL30210848 | 0.89 | MAPT (0.38) | CCNA2CDK2MAPTMEN1KMT2A | |
| SCHEMBL23930498 | 0.89 | MAPT (0.38) | CCNA2CDK2MAPTMEN1KMT2A | |
| SCHEMBL23930469 | 0.89 | MAPT (0.38) | CCNA2CDK2MAPTMEN1KMT2A | |
| SCHEMBL23930622 | 0.89 | MAPT (0.38) | CCNA2CDK2MAPTMEN1KMT2A | |
| SCHEMBL23930471 | 0.89 | MAPT (0.38) | CCNA2CDK2MAPTMEN1KMT2A | |
| SCHEMBL23930513 | 0.89 | SMN1; SMN2 (0.42) | CCNA2CDK2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | claimed |
| EP-4139287-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2023-03-01 | — | — | EP | claimed |
| WO-2021214020-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-28 | — | — | WO | claimed |
| EP-4139287-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| EP-4139287-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2023-03-01 | — | — | EP | disclosed |
| CN-115697979-A | Substituted aminothiazoles as DGKZETA inhibitors for immune activation | 拜耳公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021214020-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | CCNA2 836/4885CDK2 232/4885MAPT 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.